This retrospective study from the Italian Association of Pediatric Hematology Oncology-Bone Marrow Transplant Group (AIEOP-TMO) reports the results of consolidation with high-dose melphalan and autologous hematopoietic stem cell transplantation (auto-HSCT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1). From October 1994 to July 1999, 20 patients (median age 9.9 years, range 0.11-16.2) were treated in six centers. Eighteen had de novo AML and two had secondary AML. According to BFM criteria, 10 were classified as standard-and 10 as highrisk patients, respectively. The median time from diagnosis to CR1 and from diagnosis to Auto-HSCT were 1.1 months (range 0.8-1.6) and 4.3 months (range 3.1-6.2), respectively. Purging with either mafosfamide (three) or in vivo interleukin-2 (four) was performed in seven of 20 patients. Melphalan was administered at a dosage of 150-220 mg/m 2 (median 180). Median total number of nucleated cells infused was 2.5 ؋ 10 8 /kg (range 1.1-8.9). The myeloablative regimen was well tolerated with no toxic death, veno-occlusive disease or life-threatening complications. All patients had hematopoietic recovery in a median time of 27 days for neutrophils and 44 days for platelets. Eight of 20 patients relapsed after a median time of 7.2 months from transplant (range 5.7-15.9). Six of them died (five of progression of disease and one of sepsis) while the remaining two patients are alive in CR2. The 3-year cumulative probability of survival and event-free-survival (EFS) is 62% and 56%, respectively. This study showed that in Keywords: acute myeloid leukemia; pediatric autologous bone marrow transplantation; pediatric autologous hematopoietic stem cell transplantation; melphalan Prognosis of acute myeloid leukemia (AML) in childhood has considerably improved over the last decades. The strategy accounting for this success has been the adoption of intensive induction chemotherapy followed by intensive post-remission treatment with either high-dose ara-C or myeloablative regimens followed by stem cell transplantation.
pediatric patients with AML consolidation of CR1 with high-dose melphalan allows survival and EFS to be obtained comparable to other auto-HSCT or chemotherapy published series with a potential sparing effect both on duration of treatment (with respect to chemotherapy) and on long-term side-effects (with respect to auto-HSCT with TBI or busulfan containing regimens). Bone Marrow Transplantation (2001) 28, 131-136. Keywords: acute myeloid leukemia; pediatric autologous bone marrow transplantation; pediatric autologous hematopoietic stem cell transplantation; melphalan Prognosis of acute myeloid leukemia (AML) in childhood has considerably improved over the last decades. The strategy accounting for this success has been the adoption of intensive induction chemotherapy followed by intensive post-remission treatment with either high-dose ara-C or myeloablative regimens followed by stem cell transplantation. 1 Allogeneic bone marrow transplantation is the best option for AML patients in first remission provided that an HLA compatible family donor is available. 2, 3 Unfortunately, only 25-30% of potential candidates have an HLAidentical family donor. In the remaining patients, autologous hematopoietic stem cell transplantation (auto-HSCT) can be an alternative approach and its results in some series compare favorably with those of allogeneic BMT. 2 Although based on limited data, results so far reported on auto-HSCT in childhood AML in first complete remission (CR1) showed a leukemia-free survival ranging from 41% to 87%. [4] [5] [6] [7] The best conditioning regimen is still a matter of discussion because of the many different myeloablative schemes used, some of which included total body irradiation (TBI). 2 Actually, the role of TBI in favoring leukemia eradication in AML patients has been not established so far by means of randomized trials. Moreover, the recent higher cure rates give much emphasis to prevention of longterm effects possibly associated with TBI or cranial irradiation. [8] [9] [10] We report a retrospective analysis of the Italian Association of Pediatric Hematology Oncology-Bone Marrow Transplant Group (AIEOP-TMO) regarding AML patients in CR1 who underwent auto-HSCT and received high-dose melphalan (L-PAM) as conditioning regimen.
Materials and methods
The patients analyzed were retrieved from the AIEOP registry that collects data from all pediatric bone marrow transplant centers in Italy. After a formal adhesion to the study, a specially designed case report form was sent to the principal investigator of each center to obtain more details regarding both the disease and the transplant procedure.
Eligibility criteria
The study included pediatric patients with a diagnosis of AML who underwent auto-HSCT in CR1 after two or more courses of induction treatment and were conditioned only with high doses of L-PAM. Patients with promyelocytic leukaemia were excluded from the analysis. From October 1994 to July 1999, 20 patients from six transplant centers were eligible. There were 10 males and 10 females with a median age at diagnosis of 9.9 years (range 0.11-16.2). The main demographic and clinical characteristics are listed in Table 1 . 11 Trisomy 21 and secondary AML were reported in one and two cases, respectively. Secondary AML was diagnosed after an interval of 2 and 4 years in patients treated for Hodgkin's lymphoma and yolk salk tumor, respectively. The patients were divided into two subgroups (standard-and high-risk group) according to BFM definitions: children with FAB morphology M1, M2 and Auer rods, M4eo, t(8;21), inversion of chromosome 16 and blast cell reduction on day +15 to р5% were included in the standard-risk group, whereas all other patients were considered to be at high risk. 12 Ten patients belonged to the standard-risk and nine patients belonged to the high-risk group, whereas data were incomplete for one patient. Banded cytogenetic study, FISH or RT-PCR analysis was performed at diagnosis on the marrow aspirate in 17 out of 20 patients. The results are summarized in Table 1 .
Definitions
A patient was considered to be in CR when clinical signs of leukemia had disappeared and bone marrow aspirate showed a normocellular marrow, fewer than 5% blasts, and no Auer rods. More than 5% of blasts in bone marrow aspirate and/or the presence of circulating blasts and/or extramedullary disease were defined as relapse.
The first of 3 consecutive days with a neutrophil count у0.5 ϫ 10 9 /l or with an unsupported platelet count у50 ϫ 10 9 /l were defined as time of myeloid and platelet engraftment, respectively. The criteria reported by Bearman et al 13 were used to score regimen-related toxicity. The long-term effects of treatment were investigated with specific questions in the data collection form regarding the occurrence of growth impairment, dysfunction of endocrine glands, cataract formation, central nervous system disorders, and secondary malignancy in patients who survived in remission more than 12 months from transplantation.
Induction treatment protocol and intensified consolidation in the post-remission phase
The AIEOP first-line protocol for AML (LAM 92) is shown in Figure 1 . All but one of the patients received two or more courses of idarubicin, cytarabine and etoposide (ICE). One patient received a less intensive induction based on the association of cytarabine and daunomycin.
14 Patients with an HLA-identical sibling donor were given an allogeneic BMT, whereas the remaining patients underwent auto-HSCT with or without purging. For patients who underwent auto-HSCT, the reasons for omitting TBI from conditioning were as follow: age less than 18 months at transplant (three patients), previous neurological toxicity (three patients), secondary AML (two patients) and policy of the center (12 patients).
Response to chemotherapy, harvest processing and infusion of hemopoietic stem cells
The median interval between diagnosis and CR1 was 1.1 months (range 0.8-1.7). Twelve patients underwent a second course, seven patients a third course and one patient a fourth course of chemotherapy before harvest. The source of stem cells was bone marrow in 19 patients and peripheral blood in one patient. Three patients required a second harvest to achieve an adequate total number of total nucleated cells. The source of additional stem cells was bone marrow in one case and peripheral blood in two cases, respectively.
The median interval between diagnosis and auto-HSCT was 4.3 months (range 3.1-6.2). Purging was performed in seven out of 20 patients: three cases were purged with mafosfamide at a final concentration of 100 g/ml; four patients underwent an in vivo stimulation of NK activity with a 5-day course of interleukin-2 (IL-2) before harvest, followed by 12 weekly post-engraftment IL-2 courses. 15 The marrow or peripheral stem cells were cryopreserved in 10% dimethylsulfoxide using a programmed rate freezer and stored in the vapor phase of liquid nitrogen. On day 0, the hemopoietic cells were thawed in a water bath at 37°C and infused.
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Conditioning regimen and post-transplant supportive therapy
The patients were conditioned with an L-PAM dose ranging from 150 to 220 mg/m 2 (median 180 mg/m 2 ), administered by infusion over 15 min after dilution in normal saline. The total number of nucleated cells infused were 2.5 ϫ 10 8 /kg (range 1.1-8.9).
All patients had an indwelling central venous catheter and were nursed in single room or laminar air-flow beds or HEPA filtered rooms. Eight of the 20 patients received antifungal prophylaxis with fluconazole at a dose of 6 mg/kg/day until engraftment. During the aplastic phase, irradiated and filtered platelet and erythrocyte transfusions were administered in order to maintain platelets Ͼ10 ϫ 10 9 /l and hemoglobin Ͼ80 g/l, respectively. Empirical broad-spectrum antibiotic therapy was started in the case of fever. Antifungal treatment was added in the case of suspected or proven fungal infection or in the case of fever persisting more than 3 consecutive days despite broadspectrum antibiotic treatment.
Filgrastim at a dose of 5 g/kg/day was used in six of 20 patient for a median time of 21 days (range 2-27) according to the practice of centers. Trimethoprim-sulphamethoxazole prophylaxis for Pneumocystis carinii pneumonia was given once neutrophil engraftment had occurred.
Statistical analysis
Data were collected on Microsoft Access database and analyzed as of 31 March 2000. For overall and event-free survival (OS and EFS) analysis treatment failures included death from any cause and both relapse and death from any cause, respectively. The OS and EFS curves after transplantation (starting point) were calculated by the Kaplan-Meier method. Results are expressed as probability (%) with 95% confidence limits. The impact of age at diagnosis, sex, FAB morphology, leukocyte count at diagnosis, age at transplant, time interval between diagnosis and CR1 and between diagnosis and auto-HSCT, number of courses of chemotherapy before auto-HSCT (Ͻ or Ͼ of 2), purging, total number of nucleated cells infused, use of growth factors, on clinical outcome was tested in univariate analysis. The SAS package (SAS Institute, Cary, NY, USA) was used for statistical analysis of the data. The Mann-Whitney test was used for continuous variables and either 2 test or Fisher's exact test for the categorical variables. A P value of Ͻ0.05 was considered significant.
Results
All patients engrafted with a median time of 27 days for neutrophils (range 18-84) and 44 days for platelet recovery (range 16-257), respectively. During the pre-engraftment period, the median transfusion requirement was 4 units of leukocyte-depleted red cells (range 1-18) and 6 units of single donor apheresis platelets (range 2-19). Two patients were never transfused. Purging delayed significantly engraftment for platelets (P = 0.002) but not for neutrophils (P = 0.2). Major complications were infection (fever of unknown origin in seven cases, four cases of microbiologically determined infections due to Candida guillermondii, Staphylococcus epidermidis, Pseudomonas aeruginosa and cytomegalovirus, respectively) occurring during the first 100 days post transplant with a median duration of 9 days (range 4-23). All proven or suspected infections disappeared with a median of 9 days of treatment (range 4-23). Transplant-related toxicity was mild or moderate and limited to oral mucosa (grade 1: one patient; grade 2: six patients), gastrointestinal system (grade 1: seven patients), kidney (grade 1: one patient; grade 3: one patient) and liver (grade 1: one patient; grade 2: one patient). One patient experienced severe kidney damage leading to renal insufficiency. No case of veno-occlusive disease or toxic death related to transplant was reported.
Outcome
Overall, 14 of the 20 patients are alive with a median follow-up time of 2.1 years (range 0.6-5.4): 12 are in CR1 and two in CR2 4.5 and 15.5 months after relapse, respectively.
Eight patients have relapsed with a median time to relapse of 7.2 months (range 5.7-15.9) months after transplant. Six of eight children died, five of progression of disease, and one of early sepsis while the remaining two patients are alive in CR2 after chemotherapy and a second auto-HSCT, respectively.
The 3-year Kaplan-Meier estimate of OS and EFS was 62% (confidence interval: 37-87) and 56% (confidence interval: 33-79), respectively (Figure 2 ). Among the factors tested in univariate analysis, only a white blood cell count at diagnosis Ͼ10 ϫ 10 9 /l resulted significantly associated with relapse (P Ͻ 0.012). Among 10 patients evaluable for long-term effects, one case of subclinical hypothyroidism, in the patient affected by Down's syndrome, and one case of mild hypogonadism, in the patient previously treated with alkylating agents and thoraco-abdominal irradiation for metastatic Hodgkin's lymphoma at diagnosis, was reported. 
Discussion
The optimal post-remission treatment for AML is still a matter of controversy. Allogeneic BMT from an HLA matched sibling is currently considered the most effective anti-leukemic treatment available, but only 25-30% of patients have a suitable donor. 16 Moreover, recently, several authors have shown, by means of studies based on 'biological randomization', that more intensive chemotherapy regimens can result in an overall survival comparable to that of sibling BMT. [17] [18] [19] [20] The use of an unrelated volunteer as bone marrow donor is not indicated for patients in CR1 after initial induction treatment due to the still high transplant-related mortality and high incidence of acute and chronic graft-versus-host disease. However, this option may be acceptable for children with particularly adverse prognostic features such as complex cytogenetic abnormalities, late CR1 or megakaryocytic AML. 21 Although fewer data are available for children than for adults, the scenario is the same for pediatric patients. Moreover, some questions have not been addressed by controlled trials such as the need for using TBI in conditioning regimens for auto-HSCT, the efficacy of in vitro purging for auto-HSCT and the optimal administration of high-dose cytarabine (dose, number of courses) before auto-HSCT.
Our results compare favorably with other previously published pediatric auto-HSCT studies for AML in CR1. 4, 6, 7 Tiedemann et al 6 reported a 5-year EFS of 87%, using a conditioning regimen based on chemotherapy without TBI (and, in this case, without purging). A possible explanation of the good results of that study is the optimal quality of CR1 obtained with an intensive induction treatment including high-dose cytarabine. The total dose of cytarabine, ranging from 12 to 30 g, was modulated on the results of bone marrow aspirate performed at day 14. Indeed, there is evidence of a superiority of high-dose vs intermediatedose cytarabine in patients with AML 22 and the introduction of at least one course of high-dose cytarabine is the common feature of all studies showing results of chemotherapy treatment that approach or equal those obtained with auto-HSCT or allogeneic bone marrow transplantation.
1,2,12 Also, Bonetti et al 5 recently reported a 5-year disease-free survival of 68% for patients given auto-HSCT after a conditioning regimen comprising TBI and high-dose L-PAM. In this latter study, major differences that could in part explain the better results obtained were not in the induction treatment (that was given according to AIEOP protocols for most patients (39 out of 53) but in the auto-HSCT procedure that included, besides TBI, in vivo or in vitro bone marrow purging in all patients but one. By contrast, the results of our study combined a mix of purged and unpurged autografts. Only three patients received a bone marrow purged in vitro with mafosfamide, a drug able to eliminate residual leukemic cells. 23 Potentially, the extension of the in vitro purging to all patients could improve the EFS but, to date, such data have not been tested in a randomized study. 2 Four patients received a 5-day course of IL-2 before marrow collection followed by 12 IL-2 courses after engraftment in order to stimulate immune functions and NK cell activity. 15 This strategy has been suggested by results of small pilot studies on relapsed patients or patients in CR2 24, 25 but its efficacy deserves further confirmation.
The conditioning regimen with only high-dose L-PAM was well tolerated with no toxic death, veno-occlusive disease or life-threatening complications. Extrahematological regimen-related toxicity was mild or moderate and limited mainly to oral and gastrointestinal symptoms. These findings confirm the good tolerability of high-dose L-PAM in pediatric auto-HSCT as previously reported by Tiedemann et al 6 and compares favorably with the treatment-related mortality of different regimens. In fact, a randomized study of autologous transplantation vs intensive consolidation chemotherapy for AML in childhood reported a treatmentrelated mortality as high as 15% in the ABMT arm with a conditioning regimen based on busulfan and cyclophosphamide 26 while adding TBI to high-dose L-PAM is associated with a TRM incidence as high as 4%, with hemorrhage and infection being the causes of death. 5 Another aspect deserving particular emphasis, concomitant with the improved cure rate, is the prevention of long-term effects. Hypothyroidism, growth impairment and cataract formation have been associated with TBI containing regimens whilst sterility has been described after both TBI 8 and busulfan containing regimens.
2 Also, the strategy to cure pediatric AML with chemotherapy alone without auto-HSCT intensification such as BFM trials, 12 although apparently less toxic, has a potential risk of the development of neurocognitive abnormalities and endocrine dysfunction because of the administration of cranial irradiation. 27 In this study, the short follow-up did not allow any definitive conclusions about long-term side-effects of high-dose L-PAM but the only side-effects observed so far are mild dysfunction of thyroid and gonads that were considered more likely associated with constitutional underlying disease (Down's syndrome) in one patient and to previous first-line treatment with alkylating agents and thoraco-abdominal irradiation in the other.
In conclusion, this retrospective study showed that in pediatric patients with AML, consolidation of CR1 with high-dose L-PAM achieved survival and EFS rates comparable to other published series of auto-HSCT and chemotherapy with a potential sparing effect on the duration of treatment (with respect to chemotherapy) and on the longterm side-effects (with respect to auto-HSCT with TBI or busulfan containing regimens). Whether the use of TBI in addition to L-PAM increases the chance of cure of children with AML in CR1 should be studied in future randomized trials.
